Clinical Trial Update: Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of the AT-Patch wearable ECG in hypertrophic cardiomyopathy patients requiring 48-hour Holter monitori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• AT-Patch

Snippet

Sponsor: Yonsei University | Conditions: Hypertrophic Cardiomyopathy | Phase 3 | Status: NOT_YET_RECRUITING